Abstract
Inflammatory arthropathies such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis are extremely common in the community, with a prevalence of up to 5%, and they cause substantial morbidity. The development of anti-TNF agents for use initially in rheumatoid arthritis, and subsequently more broadly in inflammatory arthritis, represents the biggest advance in management of these conditions since the introduction of corticosteroid agents, and is a major vindication of public funded arthritis research. However, there are limitations of even these highly effective agents. A significant minority of patients with inflammatory arthritis do not respond to these anti-TNF agents, they are associated with substantial risk of toxicity, require parenteral administration, and are extremely expensive. New antibody treatments in development can be divided into anti-cytokine agents, cell-targeted therapies, co-stimulation inhibitors, and treatments aimed at preventing joint erosion consequent on inflammation. This review discusses the state of the art in the development of these agents for management of this common group of diseases.
Keywords: inflammation, il-1, anti-tnf agents, t-cell depletion, cytotoxic-lymphocyte-associated antigen 4, anti-osteoclast therapies
Current Medicinal Chemistry
Title: Antibody Treatments of Inflammatory Arthritis
Volume: 12 Issue: 25
Author(s): Matthew A. Brown
Affiliation:
Keywords: inflammation, il-1, anti-tnf agents, t-cell depletion, cytotoxic-lymphocyte-associated antigen 4, anti-osteoclast therapies
Abstract: Inflammatory arthropathies such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis are extremely common in the community, with a prevalence of up to 5%, and they cause substantial morbidity. The development of anti-TNF agents for use initially in rheumatoid arthritis, and subsequently more broadly in inflammatory arthritis, represents the biggest advance in management of these conditions since the introduction of corticosteroid agents, and is a major vindication of public funded arthritis research. However, there are limitations of even these highly effective agents. A significant minority of patients with inflammatory arthritis do not respond to these anti-TNF agents, they are associated with substantial risk of toxicity, require parenteral administration, and are extremely expensive. New antibody treatments in development can be divided into anti-cytokine agents, cell-targeted therapies, co-stimulation inhibitors, and treatments aimed at preventing joint erosion consequent on inflammation. This review discusses the state of the art in the development of these agents for management of this common group of diseases.
Export Options
About this article
Cite this article as:
Brown A. Matthew, Antibody Treatments of Inflammatory Arthritis, Current Medicinal Chemistry 2005; 12 (25) . https://dx.doi.org/10.2174/092986705774462842
DOI https://dx.doi.org/10.2174/092986705774462842 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Skin Photoprotection by Green Tea: Antioxidant and Immunomodulatory Effects
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Blood Derivates in Ocular Surface Regeneration
Recent Patents on Regenerative Medicine Editorial (Thematic Issue: Rheumatic Diseases as the Fuel to Inflamm-aging)
Current Aging Science The Role of Tai Chi in Mental Health Management—Lessons Learned from Clinical Trials
Reviews on Recent Clinical Trials Insight, Outcome and Recovery in Schizophrenia Spectrum Disorders: An Examination of their Paradoxical Relationship
Current Psychiatry Reviews Role and Function of Adenosine and its Receptors in Inflammation, Neuroinflammation, IBS, Autoimmune Inflammatory Disorders, Rheumatoid Arthritis and Psoriasis
Current Pharmaceutical Design STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Role of Invariant Natural Killer T (iNKT) Cells in Systemic Lupus Erythematosus
Current Medicinal Chemistry Exploring Interaction of TNF and Orthopoxviral CrmB Protein by Surface Plasmon Resonance and Free Energy Calculation
Protein & Peptide Letters Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Respiration and Energy Homeostasis
Current Respiratory Medicine Reviews Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Rheumatoid Arthritis and Cardiovascular Risk: Between Lights and Shadows
Current Rheumatology Reviews The Role of Extracellular Nucleic Acids in Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry Protein Transduction Domains: Applications for Molecular Medicine
Current Gene Therapy Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry NF-κB Links Keratinocytes and Lymphocytes in the Pathogenesis of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery